Maxigen Biotech Inc Working Capital to Net Assets Ratio
Maxigen Biotech Inc working capital to net assets ratio. Maxigen Biotech Inc (1783) has a Working Capital to Net Assets ratio of 47.1% as of June 2026. Working capital of NT$706.35 Million (current assets of NT$1.24 Billion minus current liabilities of NT$529.80 Million) is measured against net assets of NT$1.50 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Maxigen Biotech Inc (1783) tangible equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Maxigen Biotech Inc (2009–2025)
Working capital to net assets ratio of Maxigen Biotech Inc from 2009 to 2025. This chart shows how Maxigen Biotech Inc's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2009 to 2025. As of June 2026, the ratio stands at 47.1%, reflecting working capital of NT$706.35 Million against net assets of NT$1.50 Billion TWD. See 1783 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Maxigen Biotech Inc Working Capital to Net Assets Ratio by Year (2009–2025)
Maxigen Biotech Inc working capital to net assets ratio by year from 2009 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Maxigen Biotech Inc from 2009 to 2025, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 1783 total asset value.
| Year | WC/NA Ratio | Working Capital (TWD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 50.2% | NT$772.36 Million | NT$1.54 Billion | NT$1.12 Billion | NT$349.11 Million | ▲ +4.8 pp |
| 2024 | 45.4% | NT$624.47 Million | NT$1.38 Billion | NT$830.33 Million | NT$205.87 Million | ▲ +9.5 pp |
| 2023 | 35.9% | NT$488.19 Million | NT$1.36 Billion | NT$619.56 Million | NT$131.37 Million | ▼ -29.1 pp |
| 2022 | 65.0% | NT$841.75 Million | NT$1.30 Billion | NT$993.25 Million | NT$151.50 Million | ▲ +6.5 pp |
| 2021 | 58.5% | NT$667.49 Million | NT$1.14 Billion | NT$783.55 Million | NT$116.07 Million | ▲ +18.3 pp |
| 2020 | 40.2% | NT$345.47 Million | NT$860.23 Million | NT$432.06 Million | NT$86.58 Million | ▲ +2.8 pp |
| 2019 | 37.4% | NT$318.20 Million | NT$851.32 Million | NT$640.15 Million | NT$321.95 Million | ▲ +0.9 pp |
| 2018 | 36.4% | NT$307.14 Million | NT$842.98 Million | NT$599.52 Million | NT$292.39 Million | ▼ -26.6 pp |
| 2017 | 63.1% | NT$502.12 Million | NT$796.25 Million | NT$585.10 Million | NT$82.98 Million | ▲ +0.8 pp |
| 2016 | 62.2% | NT$486.34 Million | NT$781.38 Million | NT$574.01 Million | NT$87.68 Million | ▼ -14.8 pp |
| 2015 | 77.0% | NT$639.20 Million | NT$829.86 Million | NT$702.54 Million | NT$63.34 Million | ▲ +9.4 pp |
| 2014 | 67.6% | NT$593.03 Million | NT$877.01 Million | NT$658.09 Million | NT$65.06 Million | ▼ -15.6 pp |
| 2013 | 83.2% | NT$739.30 Million | NT$888.39 Million | NT$788.21 Million | NT$48.91 Million | ▲ +7.2 pp |
| 2012 | 76.0% | NT$292.99 Million | NT$385.66 Million | NT$333.02 Million | NT$40.04 Million | ▲ +1.9 pp |
| 2011 | 74.1% | NT$273.45 Million | NT$369.25 Million | NT$310.79 Million | NT$37.34 Million | ▼ -13.2 pp |
| 2010 | 87.2% | NT$344.81 Million | NT$395.39 Million | NT$379.11 Million | NT$34.30 Million | ▲ +5.2 pp |
| 2009 | 82.0% | NT$256.81 Million | NT$313.03 Million | NT$287.26 Million | NT$30.45 Million | — |